GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that on 20 March 2026 it repurchased 560,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 1,940.50p to 1,967.50p per share, with a volume‑weighted average price of 1,953.58p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 13,331,521 ordinary shares. After this transaction, it holds 253,222,615 shares in treasury and has 4,062,953,663 ordinary shares in issue excluding treasury, which is also the total number of voting rights. Treasury shares represent 6.23% of voting rights.
GSK plc reports that it bought back 650,000 ordinary shares on 19 March 2026 through BNP Paribas as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were acquired at a volume‑weighted average price of 1,954.04p, within a range of 1,944.50p to 1,975.50p per share.
The shares will be held as treasury shares. Since 17 February 2026, GSK has purchased 12,771,521 ordinary shares under this programme. After this transaction, the company holds 252,662,615 shares in treasury and has 4,063,508,150 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.22% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc reports that the US FDA has approved Lynavoy (linerixibat) to treat cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). Lynavoy is an ileal bile acid transporter (IBAT) inhibitor and is the first medicine approved in the US specifically for this indication.
The approval is supported by the phase III GLISTEN trial, which met its primary and key secondary endpoints, showing significant, rapid (by week two) and sustained (over 24 weeks) reductions in itch and itch-related sleep interference versus placebo. The most common side effects were diarrhoea and abdominal pain, generally mild to moderate.
GSK previously signed a licence agreement for Alfasigma S.p.A. to acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, with this transaction still subject to customary regulatory clearances. Regulatory reviews for linerixibat are also underway in the EU, UK, Canada and China, and the drug has Orphan Drug Designation in the US and Japan and priority review in China.
GSK plc filed a report describing a small insider share purchase. Chief People Officer Diana Conrad acquired American Depositary Shares under a GSK pension plan. She bought 12.430 ADS at a price of $54.4100 per ADS on 2026-03-16 on the New York Stock Exchange.
GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. The transaction involved 129.152 ADS at a price of $53.3900 per ADS on 2026-03-13 on the New York Stock Exchange.
These are plan-related notional ADS rather than a standard open-market purchase, reflecting additional equity-linked compensation within her executive savings account.
GSK plc reports that it repurchased 628,000 ordinary shares on 16 March 2026 under its existing share buyback programme, acting through BNP Paribas. The shares were bought at prices between 2,026.00p and 2,052.00p per share, with a volume‑weighted average price of 2,035.82p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 10,553,409 ordinary shares. After this transaction, GSK holds 250,444,503 shares in treasury and has 4,065,726,262 ordinary shares in issue, all carrying voting rights.
The total number of voting rights in GSK is stated as 4,065,726,262, and the company notes that treasury shares represent 6.16% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that on 13 March 2026 it repurchased 445,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,027.00p to 2,060.00p per share, with a volume‑weighted average price of 2,041.70p.
The shares bought will be held as treasury shares. Since 17 February 2026, GSK has repurchased 9,925,409 ordinary shares. After this transaction, it holds 249,816,503 shares in treasury and has 4,066,354,262 ordinary shares in issue and voting rights, with treasury shares representing 6.14% of voting rights.
GSK plc reports that the US FDA has expanded the approved age indication for its RSV vaccine Arexvy to adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by RSV. Arexvy was previously approved in the US for adults 60 and older, and for adults 50-59 at increased risk. GSK notes that an estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, and that RSV drives about 17,000 hospitalisations and 1.97 million outpatient visits annually among adults 18-49 years. The label expansion is supported by a Phase IIIb trial showing a non-inferior immune response versus adults 60 and above, with a safety profile consistent with earlier Phase III data.
GSK plc reported that several senior leaders acquired small amounts of equity through company share plans. On March 10, 2026, executives including the President, Europe; Chief Financial Officer; Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO, ViiV Healthcare and President, Global Health; and the SVP & Company Secretary each acquired 12 Ordinary Shares of 31¼ pence at £20.7168 per share under GSK's Share Reward Plan on the London Stock Exchange.
In a separate transaction on March 9, 2026, President Maya Martinez-Davis acquired 2.150 notional American Depositary Shares at $55.5100 within her GSK Executive Supplemental Savings Plan account on the New York Stock Exchange.
GSK plc reports that on 11 March 2026 it repurchased 513,409 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought between 2,047.00p and 2,078.00p at a volume-weighted average price of 2,061.69p and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased 8,690,409 shares. After this transaction, it holds 248,581,503 shares in treasury and has 4,067,587,319 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.11% of voting rights.